2型糖尿病治疗药物经济学评价模型的分析研究(6)
[15] GOURZOULIDIS G,TZANETAKOS C,IOANNIDIS I,et al. Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece[J]. Clin Drug Investig,2018,38(5):417-426.[16] NGUYEN E,COLEMAN C I,NAIR S,et al. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk[J]. J Diabet Complications ......
您现在查看是摘要页,全文长 3508 字符。